MAPT and early-onset autosomal dominant Alzheimer disease: It has been shown that liraglutide reduces neuroinflammation, reduces tau phosphorylation mediated by PI3K/Akt/GSK3β signaling27, attenuates toxic protein buildup and improves synaptic function in transgenic animal models of Alzheimer’s disease, all of which could decrease gray matter atrophy and ultimately provide protection against cognitive decline.